Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

Table 5 Associations of endpoints with SNP CYP19A1 rs10046 variants, overall and according to treatment assignments

		CYP19A1: rs10046
Endpoint	Cohort	T/T vs T/C, C/C patients (events)	Univariate model OR (95 % CI)^a	Univariate model Interaction P value^b	Multivariable model OR (95 % CI)^c
Hot flashes/sweating	All patients	446 (172) vs 1519 (676)	0.78 (0.63, 0.97)	0.03	0.83 (0.66, 1.03)
	Exemestane + OFS	227 (77) vs 759 (334)	0.65 (0.48, 0.89)		0.67 (0.49, 0.93)
	Tamoxifen + OFS	219 (95) vs 760 (342)	0.94 (0.69, 1.27)		1.04 (0.75, 1.43)
Musculoskeletal events	All patients	446 (110) vs 1520 (406)	0.90 (0.70, 1.15)	0.39	0.85 (0.66, 1.1)
	Exemestane + OFS	227 (75) vs 759 (256)	0.97 (0.71, 1.33)		0.96 (0.69, 1.32)
	Tamoxifen + OFS	219 (35) vs 761 (150)	0.77 (0.52, 1.16)		0.77 (0.51, 1.17)

^aEstimates from univariate logistic regression model. ^b P value from test of rs10046 variants ((T/T) vs. T/C, C/C) by treatment interaction in logistic regression model (univariable) assessing association between the SNP variants and early-onset adverse events in the overall cohort. ^cAdjusted for baseline characteristics: age, menstrual status, body mass index, adjuvant chemotherapy use, treatment assignment (for “all patients” cohort), baseline hot flashes/sweating or baseline musculoskeletal symptoms (according to endpoint) and prior to or baseline concomitant medications use and use during relevant time period for the endpoint (yes or no). SNP single nucleotide polymorphism, OFS ovarian function suppression, OR odds ratio, CI confidence interval

ISSN: 1465-542X